ArticleAdvances in therapy2019

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.

Lawrence Blonde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.